Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Building Equitable Access to Mechanical Circulatory Support in Latin America: Reflecting on the Accomplishment of Utilizing the First Impella 5.5 p-VAD in Mexico.

Created on 03 Oct 2026

Authors

Mauricio Castillo-Perez, Vicente Jimenez-Franco, Carlos Jerjes-Sanchez, Guillermo Quezada-Valenzuela, Luis Arturo Ramirez-Valdivia, Jose Gildardo Paredes-Vazquez, Francisco Lima-Lopez, Rene Gomez-Gutierrez, Arvind Bhimaraj, Guillermo Torre-Amione

Published in

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. Oct 02, 2026. Epub Oct 02, 2026.

Abstract

Mechanical circulatory support (MCS) has transformed the management of advanced heart failure (HF) and cardiogenic shock (CS), yet access remains profoundly unequal across healthcare systems. Following regulatory approval in Mexico, our institution performed the first Impella 5.5 implantation in Latin America in a patient undergoing high-risk Bentall surgery. Pre-emptive temporary MCS (t-MCS) enabled hemodynamic stabilization, recovery of end-organ function, optimization of medical therapy, mobilization, and rehabilitation. At 6-month follow-up the patient was in NYHA class I with recovery of left ventricular ejection fraction (LVEF) from 30% to 56%. Beyond the clinical outcome, this experience highlights both what is possible and four major barriers to expanding MCS in Latin America: regulatory delays, financial constraints, the need for multidisciplinary HF and CS programs, and the scarcity of region-specific evidence. Addressing these disparities will require coordinated international action, including a consortium focused on global advanced HF inequity, multinational data platforms, exchange of cost-effective regional solutions, and streamlined regulatory pathways for validated technologies. This experience should therefore serve not merely as a technological milestone, but as a catalyst for sustainable and equitable access to advanced HF therapies across Latin America and other resource-constrained healthcare systems.

PMID:
42826811
Bibliographic data and abstract were imported from PubMed on 03 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 25
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement